BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38182898)

  • 1. Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers.
    Jessen M; Gertzmann D; Liss F; Zenk F; Bähner L; Schöffler V; Schulte C; Maric HM; Ade CP; von Eyss B; Gaubatz S
    Oncogene; 2024 Feb; 43(8):578-593. PubMed ID: 38182898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Myb-MuvB Complex Is Required for YAP-Dependent Transcription of Mitotic Genes.
    Pattschull G; Walz S; Gründl M; Schwab M; Rühl E; Baluapuri A; Cindric-Vranesic A; Kneitz S; Wolf E; Ade CP; Rosenwald A; von Eyss B; Gaubatz S
    Cell Rep; 2019 Jun; 27(12):3533-3546.e7. PubMed ID: 31216474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
    Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatic Hypermutation of the
    Zhang X; Tang JZ; Vergara IA; Zhang Y; Szeto P; Yang L; Mintoff C; Colebatch A; McIntosh L; Mitchell KA; Shaw E; Rizos H; Long GV; Hayward N; McArthur GA; Papenfuss AT; Harvey KF; Shackleton M
    Mol Cancer Res; 2019 Jul; 17(7):1435-1449. PubMed ID: 30833299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Furry protein suppresses nuclear localization of yes-associated protein (YAP) by activating NDR kinase and binding to YAP.
    Irie K; Nagai T; Mizuno K
    J Biol Chem; 2020 Mar; 295(10):3017-3028. PubMed ID: 31996378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of YAP with the Myb-MuvB (MMB) complex defines a transcriptional program to promote the proliferation of cardiomyocytes.
    Gründl M; Walz S; Hauf L; Schwab M; Werner KM; Spahr S; Schulte C; Maric HM; Ade CP; Gaubatz S
    PLoS Genet; 2020 May; 16(5):e1008818. PubMed ID: 32469866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. β-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in Cholangiocarcinoma.
    Zhang Y; Xu H; Cui G; Liang B; Chen X; Ko S; Affo S; Song X; Liao Y; Feng J; Wang P; Wang H; Xu M; Wang J; Pes GM; Ribback S; Zeng Y; Singhi A; Schwabe RF; Monga SP; Evert M; Tang L; Calvisi DF; Chen X
    Gastroenterology; 2022 Aug; 163(2):481-494. PubMed ID: 35489428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of AP-1 by YAP/TAZ contributes to cell proliferation and organ growth.
    Koo JH; Plouffe SW; Meng Z; Lee DH; Yang D; Lim DS; Wang CY; Guan KL
    Genes Dev; 2020 Jan; 34(1-2):72-86. PubMed ID: 31831627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in cutaneous melanoma.
    Nallet-Staub F; Marsaud V; Li L; Gilbert C; Dodier S; Bataille V; Sudol M; Herlyn M; Mauviel A
    J Invest Dermatol; 2014 Jan; 134(1):123-132. PubMed ID: 23897276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides.
    Zhou Z; Hu T; Xu Z; Lin Z; Zhang Z; Feng T; Zhu L; Rong Y; Shen H; Luk JM; Zhang X; Qin N
    FASEB J; 2015 Feb; 29(2):724-32. PubMed ID: 25384421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the Hippo/YAP/TAZ signalling pathway: Novel opportunities for therapeutic interventions into skin cancers.
    Howard A; Bojko J; Flynn B; Bowen S; Jungwirth U; Walko G
    Exp Dermatol; 2022 Oct; 31(10):1477-1499. PubMed ID: 35913427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YAP antagonizes TEAD-mediated AR signaling and prostate cancer growth.
    Li X; Zhuo S; Cho YS; Liu Y; Yang Y; Zhu J; Jiang J
    EMBO J; 2023 Feb; 42(4):e112184. PubMed ID: 36588499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Collagen abundance controls melanoma phenotypes through lineage-specific microenvironment sensing.
    Miskolczi Z; Smith MP; Rowling EJ; Ferguson J; Barriuso J; Wellbrock C
    Oncogene; 2018 Jun; 37(23):3166-3182. PubMed ID: 29545604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TEA Domain Transcription Factor 4 Is the Major Mediator of Yes-Associated Protein Oncogenic Activity in Mouse and Human Hepatoblastoma.
    Zhang J; Liu P; Tao J; Wang P; Zhang Y; Song X; Che L; Sumazin P; Ribback S; Kiss A; Schaff Z; Cigliano A; Dombrowski F; Cossu C; Pascale RM; Calvisi DF; Monga SP; Chen X
    Am J Pathol; 2019 May; 189(5):1077-1090. PubMed ID: 30794805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YAP and TAZ are transcriptional co-activators of AP-1 proteins and STAT3 during breast cellular transformation.
    He L; Pratt H; Gao M; Wei F; Weng Z; Struhl K
    Elife; 2021 Aug; 10():. PubMed ID: 34463254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain.
    Lamar JM; Stern P; Liu H; Schindler JW; Jiang ZG; Hynes RO
    Proc Natl Acad Sci U S A; 2012 Sep; 109(37):E2441-50. PubMed ID: 22891335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SKP2- and OTUD1-regulated non-proteolytic ubiquitination of YAP promotes YAP nuclear localization and activity.
    Yao F; Zhou Z; Kim J; Hang Q; Xiao Z; Ton BN; Chang L; Liu N; Zeng L; Wang W; Wang Y; Zhang P; Hu X; Su X; Liang H; Sun Y; Ma L
    Nat Commun; 2018 Jun; 9(1):2269. PubMed ID: 29891922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a derivative of the alkaloid emetine as an inhibitor of the YAP-TEAD interaction and its potential as an anticancer agent.
    Sekine S; Takase S; Hayase R; Noritsugu K; Maemoto Y; Ichikawa Y; Ogawa K; Kondoh Y; Osada H; Yoshida M; Ito A
    Biosci Biotechnol Biochem; 2023 Apr; 87(5):501-510. PubMed ID: 36809780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Hippo pathway oncoprotein YAP promotes melanoma cell invasion and spontaneous metastasis.
    Zhang X; Yang L; Szeto P; Abali GK; Zhang Y; Kulkarni A; Amarasinghe K; Li J; Vergara IA; Molania R; Papenfuss AT; McLean C; Shackleton M; Harvey KF
    Oncogene; 2020 Jul; 39(30):5267-5281. PubMed ID: 32561850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TFCP2 Is Required for YAP-Dependent Transcription to Stimulate Liver Malignancy.
    Zhang X; Sun F; Qiao Y; Zheng W; Liu Y; Chen Y; Wu Q; Liu X; Zhu G; Chen Y; Yu Y; Pan Q; Wang J
    Cell Rep; 2017 Oct; 21(5):1227-1239. PubMed ID: 29091762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.